Accolate

• Anti-Asthmatic Agents
• Leukotriene Antagonists
• ATC:R03DC01

• Accolate
• Zafirlukast [Usan:Ban:Inn]

No information avaliable

C₃₁H₃₃N₃O₆S

http://www.rxlist.com/cgi/generic/zafirlukast.htm

Accolate FDA

Accolate MSDS

FJ Brown et al. Eur. pat. Appl. 199.543; PR Bernstein et al, US Pat.. 4.859.692 (1986, 1989 sia per l'ICI)

575.676 g/mol

139 ^oC

Nessuna informazione disponibile

Solid

5.787

Compressa

Per la profilassi e nel trattamento cronico dell'asma.

Zafirlukast è un prodotto sintetico, peptide antagonista selettivo del recettore dei leucotrieni (LTRA) indicato per la profilassi e nel trattamento cronico dell'asma. I pazienti con asma sono stati trovati in uno studio di 25 - 100 volte più sensibili alle attività broncocostrittori di LTD4 per via inalatoria rispetto ai soggetti non asmatici. Studi in vitro hanno dimostrato che zafirlukast antagonizzata l'attività contrattile di tre leucotrieni (LTC4, LTD4 e LTE4) nella conduzione di muscolatura liscia delle vie aeree da animali da laboratorio ed esseri umani. Zafirlukast impedito intradermica LTD4 indotto aumenti di permeabilità vascolare cutanea e inibito per via inalatoria LTD4 indotta afflusso di eosinofili nei polmoni degli animali.

Rapidamente assorbito dopo somministrazione orale, riduce dopo un pasto ricco di grassi o ad alto contenuto proteico.

Gli effetti collaterali includono eruzioni cutanee e disturbi allo stomaco.

Patients should be told that a rare side effect of ACCOLATE is hepatic dysfunction, and to contact their physician immediately if they experience symptoms of hepatic dysfunction (eg. right upper quadrant abdominal pain, nausea, fatigue, lethargy, pruritus, jaundice, flu-like symptoms, and anorexia). Liver failure resulting in liver transplantation and death has occurred in patients taking zafirlukast .

ACCOLATE is indicated for the chronic treatment of asthma and should be taken regularly as prescribed, even during symptom-free periods. ACCOLATE is not a bronchodilator and should not be used to treat acute episodes of asthma. Patients receiving ACCOLATE should be instructed not to decrease the dose or stop taking any other antiasthma medications unless instructed by a physician. Women who are breast-feeding should be instructed not to take ACCOLATE. Alternative antiasthma medication should be considered in such patients.

The bioavailability of ACCOLATE may be decreased when taken with food. Patients should be instructed to take ACCOLATE at least 1 hour before or 2 hours after meals.

Eosinophilic Conditions: In rare cases, patients on ACCOLATE therapy may present with systemic eosinophilia, eosinophilic pneumonia, or clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic steroid therapy. These events usually, but not always, have been associated with the reduction of oral steroid therapy. Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal association between ACCOLATE and these underlying conditions has not been established .

Gli esseri umani e altri mammiferi